AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7681769
Drug: Synthetic porcine
RxNorm normalized name: Secretin synthetic porcine
DrugBank: Secretin porcine (DB09527)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synthetic porcine galanin IV, 500 micrograms in 100 mL
Trial: 7681769
Drug: Saline IV,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline IV, 100 mL
Trial: 2405141
Drug: Human surfactant
RxNorm normalized name: recombinant human surfactant protein D
DrugBank: Zelpultide alfa (DB18587)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human surfactant treatment
Trial: 31495382
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of alcohol (one standard drink)
Trial: 31495382
Drug: g/kg dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: g/kg dosing of alcohol (controlling for gender)
Trial: 26608256
Drug: Liraglutide (1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (1.8 mg daily)
Trial: 24992552
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (BDP) nasal aerosol at 320 μg once daily
Trial: 15741004
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (Amitriptyline and Fluvoxamine)
Trial: 10561206
Drug: Low-dose chemotherapy
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose chemotherapy (doxorubicin 20 mg/m(2), vincristine 1 mg/m(2) on day 1; cyclophosphamide 300 mg/m(2); methotrexate 25 mg/m(2); fluorouracil 600 mg/m(2) on days 29 and 36) plus tamoxifen 20 mg orally for 2 years
Trial: 10561206
Drug: Tamoxifen 20
RxNorm normalized name: tamoxifen 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 20 mg orally for 2 years
Trial: 10561206
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (terminated group)
Trial: 8568142
Drug: Oral cow
RxNorm normalized name: Cow milk
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cow milk challenges
Trial: 6885683
Drug: Amoxycillin 250
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxycillin 250 mg tds
Trial: 31962329
Drug: Traditional medicine-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional medicine-based diet and lifestyle recommendations for at least 3 months
Trial: 31962329
Drug: Traditional medicine-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional medicine-based diet and lifestyle recommendations
Trial: 11687542
Drug: Indomethacin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (5 mg/kg) pretreatment
Trial: 3070369
Drug: Indomethacin (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (0.2 mg/kg, 3 times p.o. in 12 h intervals starting on the 3rd day of life)
Trial: 3070369
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (22 VLBWI with comparable weight 1250 ± 154 g, gestational age 28.4 ± 1 weeks)
Trial: 22672773
Drug: VAC(®) therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAC(®) therapy
Trial: 22672773
Drug: Sorbalgon(®) therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorbalgon(®) therapy
Trial: 21584935
Drug: Propofol-ketamine combination
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol-ketamine combination (Group K)
Trial: 17257456
Drug: Cefdinir 300
RxNorm normalized name: cefdinir 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefdinir 300 mg BID for 10 days
Trial: 17257456
Drug: Cephalexin 250
RxNorm normalized name: cephalexin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalexin 250 mg QID for 10 days
Trial: 15029134
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of diet and aerobic exercise
Trial: 25374138
Drug: Nicardipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine (20 μg/kg)
Trial: 25374138
Drug: Control (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (5 ml saline)
Trial: 24620386
Drug: Xuebijing injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuebijing injection (100 mL added to 0.9% saline for 3 days preoperatively)
Trial: 24620386
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no Xuebijing injection)
Trial: 21933609
Drug: Benazepril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril (10 mg per day for at least 3 days before procedure)
Trial: 16813587
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy with oxaliplatin and irinotecan
Trial: 16813587
Drug: Targeted agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted agents bevacizumab and cetuximab
Trial: 16813587
Drug: Neo-adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neo-adjuvant chemotherapy prior to preoperative CRT
Trial: 9250454
Drug: Lys(B28), Pro(B29)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lys(B28), Pro(B29) human insulin analog (insulin lispro)
Trial: 3613693
Drug: Buspirone 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone 25 mg
Trial: 3613693
Drug: Buspirone 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone 50 mg
Trial: 3613693
Drug: Buspirone 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone 100 mg
Trial: 26057685
Drug: Original Youth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Original Youth Fit For Life treatment
Trial: 20683051
Drug: Sequential administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential administration of cisplatin-etoposide followed by topotecan (arm A)
Trial: 20683051
Drug: Alternate administration
RxNorm normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternate administration of cisplatin-etoposide and topotecan (arm B)
Trial: 14522530
Drug: Selective decontamination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective decontamination of the digestive tract (SDD) with oral and enteral polymyxin E, tobramycin, and amphotericin B combined with an initial 4-day course of intravenous cefotaxime
Trial: 11004613
Drug: OKTcdr4a 225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OKTcdr4a 225 mg/course (low dose)
Trial: 11004613
Drug: OKTcdr4a 750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OKTcdr4a 750 mg/course (high dose)
Trial: 11004613
Drug: OKTcdr4a 750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OKTcdr4a 750 mg/course (high dose) after initial treatment
Trial: 11004613
Drug: Placebo or
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo or low-dose OKTcdr4a followed by high-dose OKTcdr4a
Trial: 9122545
Drug: Intact milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intact milk (240 or 360 mL)
Trial: 9122545
Drug: Hydrolyzed milk
RxNorm normalized name: collagen, hydrolyzed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrolyzed milk (240 or 360 mL)
Trial: 1296499
Drug: ioversol 300
RxNorm normalized name: IOVERSOL 300MG/ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ioversol 300 mg/ml
Trial: 1296499
Drug: iohexol 300
RxNorm normalized name: IOHEXOL 300MG/ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iohexol 300 mg/ml
Trial: 6691015
Drug: Weekly pelvic
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly pelvic examinations starting at 37 weeks' gestation
Trial: 29732651
Drug: 8 weekly
RxNorm normalized name: Weekly Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 weekly 2‐hr workshop sessions
Trial: 24594499
Drug: Promethazine 25
RxNorm normalized name: promethazine 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promethazine 25 mg intravenously
Trial: 24594499
Drug: Lorazepam 2
RxNorm normalized name: lorazepam 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam 2 mg intravenously
Trial: 20159180
Drug: ACIDFORM gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACIDFORM gel (plus diaphragm)
Trial: 11881521
Drug: Acamprosate 1332
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acamprosate 1332 to 1998 mg/day
Trial: 11881521
Drug: Acamprosate with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acamprosate with psychosocial support (individual psychotherapy, group psychotherapy, behavioural therapy, brief intervention, family therapy)
Trial: 11271401
Drug: Alcohol (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.8 g/kg) prior to encoding
Trial: 11271401
Drug: Alcohol (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.8 g/kg) at retrieval
Trial: 11271401
Drug: Different drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different drug state (DS) conditions
Trial: 11271401
Drug: Same drug
RxNorm normalized name: SAMe
DrugBank: Ademetionine (DB00118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same drug state (SS)
Trial: 11271401
Drug: Different drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different drug state (DS)
Trial: 9298634
Drug: Propentofylline (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propentofylline (300 mg, three times daily 1 hour before meals)
Trial: 31758177
Drug: LID/ΔM2‐2/1030s vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LID/ΔM2‐2/1030s vaccine (105 PFU, intranasal)
Trial: 29518747
Drug: High-dose n-3
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose n-3 PUFA treatment (2 g/d)
Trial: 8644642
Drug: Pirsidomine 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirsidomine 10 mg
Trial: 8644642
Drug: Pirsidomine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirsidomine 20 mg
Trial: 8644642
Drug: Pirsidomine 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirsidomine 40 mg
Trial: 24005170
Drug: Intratympanic steroid
RxNorm normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intratympanic steroid injection (ITS)
Trial: 27881113
Drug: TAU +
RxNorm normalized name: Interferon tau
DrugBank: Interferon tau (DB16972)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAU + EFT (treatment as usual with integrated emotion-focused components)
Trial: 18165461
Drug: Zolpidem extended
RxNorm normalized name: zolpidem Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem extended release 6.25 mg
Trial: 12970227
Drug: Inhaled NO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled NO (20 ppm)
Trial: 12970227
Drug: Intravenous sildenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sildenafil (1 mg/kg in 'cath laboratory', 0.25 mg/kg post op)
Trial: 8675588
Drug: Ethanol 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol 1.0 g/kg
Trial: 8675588
Drug: Ethanol (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (any dose)
Trial: 6517563
Drug: Topical acyclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical acyclovir treatment
Trial: 30508308
Drug: D/C/F/TAF split
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D/C/F/TAF split tablet (800/150/200/10 mg)
Trial: 30508308
Drug: D/C/F/TAF crushed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D/C/F/TAF crushed tablet (800/150/200/10 mg)
Trial: 30508308
Drug: D/C/F/TAF whole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D/C/F/TAF whole tablet (800/150/200/10 mg)
Trial: 26923235
Drug: Usual activities
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual activities of daily living (CTL group)
Trial: 24527443
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of alprazolam 0.5 mg and melatonin 3 mg
Trial: 16876559
Drug: Resistance training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance training (twice a week for 16 weeks)
Trial: 12542428
Drug: Atraumatic Restorative
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atraumatic Restorative Treatment (ART) using hand instruments
Trial: 10804043
Drug: Celecoxib 100
RxNorm normalized name: celecoxib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 100 mg and 200 mg, Naproxen 500 mg twice daily
Trial: 10804043
Drug: Celecoxib 25
RxNorm normalized name: celecoxib 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 25 to 400 mg twice daily
Trial: 10804043
Drug: Celecoxib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (100 to 400 mg twice daily) and Naproxen 500 mg twice daily
Trial: 9115004
Drug: 750 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 micrograms of vaginal misoprostol after 50 mg/m2 methotrexate IM
Trial: 9115004
Drug: 500 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 micrograms of vaginal misoprostol after 50 mg/m2 methotrexate IM
Trial: 9115004
Drug: Vaginal route
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal route for second dose of misoprostol after one dose failed
Trial: 9115004
Drug: Oral route
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral route for second dose of misoprostol after one dose failed
Trial: 9115004
Drug: 60 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/m2 methotrexate
Trial: 9115004
Drug: Three vaginal
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three vaginal doses of misoprostol 8 hr apart starting on Day 5
Trial: 9115004
Drug: One vaginal
RxNorm normalized name: estrone Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One vaginal dose of misoprostol
Trial: 8262821
Drug: Surgical resection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical resection leaving positive margins followed by postoperative adjuvant therapy (majority received postoperative radiotherapy +/- chemotherapy)
Trial: 8262821
Drug: Surgical resection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical resection leaving positive margins followed by postoperative adjuvant therapy
Trial: 3985390
Drug: Epidural administration
RxNorm normalized name: epidural administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural administration of 1.5% lidocaine with 80 mg methylprednisolone (group II)
Trial: 3985390
Drug: Epidural administration
RxNorm normalized name: epidural administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural administration of preservative-free physiologic saline solution and 80 mg methylprednisolone (group I, control group)
Trial: 28363320
Drug: opioid agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: opioid agonist treatment at the time of follow-up
Trial: 28363320
Drug: no agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no agonist treatment
Trial: 25527035
Drug: Caffeine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (200 mg doses, four times daily, total daily dose of 800 mg)
Trial: 21368390
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of carnitine and coenzyme Q10
Trial: 19484178
Drug: Tumescent solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumescent solution containing lidocaine and epinephrine
Trial: 19484178
Drug: Tumescent solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumescent solution containing only epinephrine
Trial: 17208005
Drug: Modern antiemetic
RxNorm normalized name: ANTIEMETICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modern antiemetic therapy
Trial: 24859491
Drug: Imipramine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (150 mg/day)
Trial: 2787399
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group (n = 53) with occlusal interferences eliminated annually
Trial: 2787399
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (n = 46) undergoing placebo treatment
Trial: 23547047
Drug: Low-dose combination
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose combination of pioglitazone (7.5 mg/d), flutamide (62.5 mg/d), and metformin (850 mg/d) (PioFluMet)
Trial: 21334736
Drug: Everolimus-based regimen
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus-based regimen (trough concentrations 6-10 ng/mL) with enteric-coated mycophenolate sodium (1440 mg/day) and corticosteroids
Trial: 23229691
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg intravitreal triamcinolone acetonide
Trial: 16978576
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg intravitreal triamcinolone acetonide
Trial: 11708699
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of Nortesten (72 mg)
Trial: 11708699
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of Nortesten (144 mg)
Trial: 11708699
Drug: Nortesten (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nortesten (both doses)
Trial: 31619205
Drug: Combined NRT
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined NRT (nicotine patch & gum)
Trial: 31619205
Drug: Single NRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single NRT (nicotine patch)
Trial: 28189292
Drug: Oxytocin nasal
RxNorm normalized name: oxytocin Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin nasal spray (32 IE)
Trial: 22542215
Drug: Antibiotics with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics with facilitated referral (AFR)
Trial: 20571437
Drug: Ziprasidone (80‐160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone (80‐160 mg/d given twice a day, mean modal dose of 112 mg/d)
Trial: 20571437
Drug: Ziprasidone (80‐120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone (80‐120 mg/d given every day, mean modal dose of 96 mg/d)
Trial: 20571437
Drug: Haloperidol (5‐20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (5‐20 mg/d, mean modal dose of 12 mg/d)
Trial: 17919155
Drug: Group music
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group music therapy (n = 21)
Trial: 19902288
Drug: Preoperative and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative and postoperative chemotherapy
Trial: 12149204
Drug: Low-dose Methotrexate
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Methotrexate (LDMTX: 6 oral doses of 30 mg/m(2)) plus intravenous Mercaptopurine (MP: 1 g/m(2))
Trial: 12149204
Drug: High-dose Methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Methotrexate (HDMTX: intravenous 1 g/m(2)) plus intravenous Mercaptopurine (MP: 1 g/m(2))
Trial: 12149204
Drug: Mercaptopurine (MP:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mercaptopurine (MP: 1 g/m(2)) alone
Trial: 12149204
Drug: High-dose Methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Methotrexate plus Mercaptopurine (HDMTX + MP)
Trial: 12149204
Drug: Low-dose Methotrexate
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Methotrexate plus Mercaptopurine (LDMTX + MP)
Trial: 7072708
Drug: Ibuprofen (IPF)
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen (IPF)
Trial: 23771541
Drug: Adrenaline (1/200,000,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline (1/200,000, 5 ml) during nasal packing (Group A1)
Trial: 23771541
Drug: Adrenaline (1/200,000,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline (1/200,000, 5 ml) during nasal packing with desflurane (Group A2)
Trial: 23771541
Drug: Desflurane administration
RxNorm normalized name: Desflurane
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desflurane administration (Group C)
Trial: 21358314
Drug: gemfibrozil, niacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemfibrozil, niacin and cholestyramine therapy
Trial: 21358314
Drug: lifestyle intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: lifestyle intervention and pharmacologic therapy
Trial: 19587364
Drug: Greater insulin
RxNorm normalized name: greater celandine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Greater insulin secretion
Trial: 19587364
Drug: Intensive lifestyle
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive lifestyle modification (ILS) and metformin